KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Receivables (2016 - 2025)

Eli Lilly (LLY) has disclosed Receivables for 17 consecutive years, with $20.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 51.82% year-over-year to $20.2 billion, compared with a TTM value of $20.2 billion through Dec 2025, up 51.82%, and an annual FY2025 reading of $20.2 billion, up 51.82% over the prior year.
  • Receivables was $20.2 billion for Q4 2025 at Eli Lilly, up from $19.5 billion in the prior quarter.
  • Across five years, Receivables topped out at $20.2 billion in Q4 2025 and bottomed at $6.7 billion in Q1 2021.
  • Average Receivables over 5 years is $11.0 billion, with a median of $9.6 billion recorded in 2023.
  • The sharpest move saw Receivables grew 4.82% in 2021, then skyrocketed 61.45% in 2025.
  • Year by year, Receivables stood at $8.1 billion in 2021, then increased by 5.31% to $8.6 billion in 2022, then skyrocketed by 32.45% to $11.3 billion in 2023, then increased by 17.11% to $13.3 billion in 2024, then surged by 51.82% to $20.2 billion in 2025.
  • Business Quant data shows Receivables for LLY at $20.2 billion in Q4 2025, $19.5 billion in Q3 2025, and $17.2 billion in Q2 2025.